REV-ERB ligands for treatment of anxiety disorders

用于治疗焦虑症的 REV-ERB 配体

基本信息

  • 批准号:
    8237792
  • 负责人:
  • 金额:
    $ 88.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dysregulation of the circadian rhythm is associated with several disorders of the nervous system including depression, anxiety, schizophrenia and sleep disorders. There is a clear unmet medical need for additional classes of therapeutics to treat these disorders. Anxiety disorders are a serious medical illness affecting approximately 40 million adults in the United States. Benzodiazepenes are the most commonly utilized anxiolytic drugs, but their use is associated with significant side effects including sedation, tolerance and potential for abuse. There are a number of anxiolytic drugs that are now available, but these also are less than optimal. This proposed research is based on our recent discovery that we can modulate the circadian rhythm in vivo with synthetic ligands for a particular nuclear receptor (NR), REV-ERB. REV-ERBa is an NR that has a well characterized role in the regulation of the circadian rhythm. We have found that a REV-ERB agonist that we have designed, SR9011,that has the ability to modulate the circadian rhythm in vivo also displays anxiolytic activity in mice. Interestingly, SR9011 displayed no sedative activity at a dose that exhibited anxiolytic activity. SR9011 is the first REV-ERB ligand with sufficient in vivo exposure to allow evaluation of its effects in animals; however, its pharmacodynamic and pharmcokinetic properties are far from optimal. We hypothesize that optimized synthetic REV-ERB ligands will have utility in treatment of anxiety disorders. We will address this hypothesis by focusing on the following specific aims: 1) Optimize the pharmacodynamic and pharmacokinetic properties of synthetic REV-ERB ligands for use in the CNS, 2) Evaluate the ability of synthetic REV-ERB ligands for their ability to modulate circadian behavior/physiology in vivo, 3) Optimize the anxiolytic activity of REV-ERB agonists in vivo and characterize their sedative activity and potential for abuse. We have now developed a series of very potent and efficacious REV-ERB agonists as well as antagonists that have properties that will allow for evaluation of these compounds in animal models of disease. Thus, our proposed research is highly innovative and has the potential to have high impact since this work may lead to novel drugs for the treatment of anxiety disorders as well as other behavioral disorders. PUBLIC HEALTH RELEVANCE: We discovered that the nuclear receptor REV-ERB is ligand regulated and have characterized both synthetic agonists and antagonists of this receptor. This receptor is a key regulator of the circadian rhythm and dysregulation of the circadian rhythm is associated with several disorders of the nervous system including anxiety disorders. We have discovered that REV-ERB agonists display anxiolytic activity and the goal of this proposal is to develop REV-ERB agonists with optimized pharmacodynamic and pharmacokinetic properties for use as anxiolytic agents.
描述(由申请人提供):昼夜节律失调与几种神经系统疾病有关,包括抑郁症、焦虑症、精神分裂症和睡眠障碍。对于治疗这些病症的其他类别的治疗剂存在明显未满足的医学需求。焦虑症是一种严重的医学疾病,影响着美国约4000万成年人。苯二氮卓类是最常用的抗焦虑药物,但其使用与显著的副作用相关,包括镇静、耐受性和滥用的可能性。现在有许多抗焦虑药物可用,但这些药物也不是最佳的。这项拟议的研究是基于我们最近的发现,我们可以调节体内的昼夜节律与合成配体的一个特定的核受体(NR),REV-ERB。REV-ERBa是一种NR,在昼夜节律的调节中具有良好的表征作用。我们发现,我们设计的REV-ERB激动剂SR9011具有调节体内昼夜节律的能力,在小鼠中也显示出抗焦虑活性。有趣的是,SR9011在表现出抗焦虑活性的剂量下不显示镇静活性。SR9011是第一个REV-ERB配体,其体内暴露足以评估其在动物中的作用;然而,其药效学和药代动力学特性远非最佳。我们假设,优化的合成REV-ERB配体将在治疗焦虑症的效用。我们将通过关注以下具体目标来解决这一假设:1)优化用于CNS的合成REV-ERB配体的药效学和药代动力学特性,2)评价合成REV-ERB配体调节体内昼夜节律行为/生理学的能力,3)优化REV-ERB激动剂的体内抗焦虑活性并表征其镇静活性和滥用潜力。我们现在已经开发了一系列非常强效和有效的REV-ERB激动剂以及拮抗剂,其具有允许在疾病动物模型中评价这些化合物的特性。因此,我们提出的研究是高度创新的,并有可能产生很大的影响,因为这项工作可能导致治疗焦虑症以及其他行为障碍的新药。 公共卫生关系:我们发现核受体REV-ERB是配体调节的,并且已经表征了该受体的合成激动剂和拮抗剂。该受体是昼夜节律的关键调节剂,昼夜节律的失调与包括焦虑症在内的几种神经系统疾病相关。我们已经发现REV-ERB激动剂显示出抗焦虑活性,并且该提议的目标是开发具有优化的药效学和药代动力学性质的REV-ERB激动剂以用作抗焦虑剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas P Burris其他文献

How to Make Glucocorticoids Safer.
PPARα ligands make memories
过氧化物酶体增殖物激活受体α配体形成记忆
  • DOI:
    10.1038/nchembio.2241
  • 发表时间:
    2016-11-15
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Thomas P Burris
  • 通讯作者:
    Thomas P Burris

Thomas P Burris的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas P Burris', 18)}}的其他基金

Exercise Mimetics for Dementia and Alzheimer's Disease
治疗痴呆和阿尔茨海默病的模拟运动
  • 批准号:
    10586188
  • 财政年份:
    2023
  • 资助金额:
    $ 88.35万
  • 项目类别:
Targeting REV-ERB to treat Alzheimer's disease
靶向 REV-ERB 治疗阿尔茨海默病
  • 批准号:
    10675294
  • 财政年份:
    2019
  • 资助金额:
    $ 88.35万
  • 项目类别:
ERRgamma Agonists to Treat Muscular Dystrophy
ERRgamma 激动剂治疗肌营养不良症
  • 批准号:
    9176946
  • 财政年份:
    2016
  • 资助金额:
    $ 88.35万
  • 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
  • 批准号:
    8898423
  • 财政年份:
    2012
  • 资助金额:
    $ 88.35万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8915743
  • 财政年份:
    2012
  • 资助金额:
    $ 88.35万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    8578608
  • 财政年份:
    2012
  • 资助金额:
    $ 88.35万
  • 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
  • 批准号:
    8444102
  • 财政年份:
    2012
  • 资助金额:
    $ 88.35万
  • 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
  • 批准号:
    9116001
  • 财政年份:
    2012
  • 资助金额:
    $ 88.35万
  • 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
  • 批准号:
    8370510
  • 财政年份:
    2010
  • 资助金额:
    $ 88.35万
  • 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
  • 批准号:
    8209001
  • 财政年份:
    2010
  • 资助金额:
    $ 88.35万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 88.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了